Pinnacle Associates’s Bicycle Therapeutics BCYC Stock Holding History

Pinnacle Associates’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$860K	Sell	185,410 -5,070	-3%	-$29K	0.01%	546
2025 Q4	$1.35M	Sell	190,480 -6,138	-3%	-$45.3K	0.02%	469
2025 Q3	$1.52M	Buy	196,618 +24,665	+14%	+$186K	0.02%	441
2025 Q2	$1.2M	Sell	171,953 -42,325	-20%	-$337K	0.02%	472
2025 Q1	$1.82M	Sell	214,278 -12,464	-5%	-$147K	0.03%	391
2024 Q4	$3.17M	Buy	+226,742	New	+$4.86M	0.04%	303
2024 Q3	–	Sell	-242,001	Closed	-$4.9M	–	806
2024 Q2	$4.9M	Buy	242,001 +161,911	+202%	+$3.66M	0.08%	245
2024 Q1	$1.99M	Buy	+80,090	New	+$1.7M	0.03%	371

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

GSK plc London $599M AUM

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pinnacle Associates's BCYC Position: Q1 2026 in Review

Pinnacle Associates reduced its Bicycle Therapeutics (BCYC) stake by 2.7% in Q1 2026, selling an estimated $29K and leaving 185,410 shares worth $860K. The position accounts for 0.01% of the portfolio, ranked #546.

Pinnacle Associates first reported a position in BCYC in Q1 2024 and has held it in 8 quarters since. The position peaked at $4.9M in Q2 2024. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

Pinnacle Associates held 185,410 shares of Bicycle Therapeutics worth $860K as of Q1 2026.
Pinnacle Associates sold 5,070 Bicycle Therapeutics shares in Q1 2026, an estimated $29K.
Bicycle Therapeutics made up 0.01% of Pinnacle Associates's portfolio in Q1 2026, its #546 holding.
Pinnacle Associates first reported a position in Bicycle Therapeutics in Q1 2024 and has held it in 8 quarters since.
Pinnacle Associates's Bicycle Therapeutics position peaked at $4.9M in Q2 2024.
98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.